168 related articles for article (PubMed ID: 19145322)
21. Trimetazidine in the myocardial cell mechanisms of cytoprotection.
Labrid C
Rom J Intern Med; 1998; 36(3-4):137-44. PubMed ID: 10822510
[TBL] [Abstract][Full Text] [Related]
22. [Clinical efficacy of myocardial cytoprotector trimetazidine in peri- and postmenopausal women with ischemic heart disease].
Churshin AD; Pimenov LT
Kardiologiia; 2003; 43(8):31-5. PubMed ID: 14593380
[TBL] [Abstract][Full Text] [Related]
23. [Trimetazidine (Preductal). A new approach in controlling myocardial ischemia].
Eliseev OM
Ter Arkh; 1996; 68(8):57-63. PubMed ID: 9019836
[No Abstract] [Full Text] [Related]
24. Trimetazidine improves recovery during reperfusion in isolated rat hearts after prolonged ischemia.
Ikizler M; Dernek S; Sevin B; Kural T
Anadolu Kardiyol Derg; 2003 Dec; 3(4):303-8. PubMed ID: 14675878
[TBL] [Abstract][Full Text] [Related]
25. The role of metabolic therapy with trimetazidine in effort tolerance in patients with ischemic heart disease.
Suljić U; Prnjavorac B; Bego T; Malenica M; Dujić T; Prnjavorac I; Čaušević A; Šaranović L
Med Glas (Zenica); 2018 Aug; 15(2):109-114. PubMed ID: 30047538
[TBL] [Abstract][Full Text] [Related]
26. [Trimetazidine, oxidative stress, and cell injury during myocardial reperfusion].
Ruiz-Meana M
Rev Esp Cardiol; 2005 Aug; 58(8):895-7. PubMed ID: 16053822
[No Abstract] [Full Text] [Related]
27. Trimetazidine and cardioprotection: facts and perspectives.
Tsioufis K; Andrikopoulos G; Manolis A
Angiology; 2015 Mar; 66(3):204-10. PubMed ID: 24719262
[TBL] [Abstract][Full Text] [Related]
28. Metabolic therapy for ischemic heart disease: the rationale for inhibition of fatty acid oxidation.
Stanley WC; Sabbah HN
Heart Fail Rev; 2005 Dec; 10(4):275-9. PubMed ID: 16583175
[No Abstract] [Full Text] [Related]
29. Trimetazidine effects on the damage to mitochondrial functions caused by ischemia and reperfusion.
Veitch K; Maisin L; Hue L
Am J Cardiol; 1995 Aug; 76(6):25B-30B. PubMed ID: 7645524
[TBL] [Abstract][Full Text] [Related]
30. [Myocardial cytoprotection with trimetazidine in patients with ischemic heart disease during surgical stress].
Afanas'eva IV; Goncharova LL; Miroshnichenko AG; Petrash VV; Pokrovskaia LA
Vestn Khir Im I I Grek; 1999; 158(5):34-7. PubMed ID: 10645577
[TBL] [Abstract][Full Text] [Related]
31. Effects of chronic trimetazidine treatment on myocardial preconditioning in anesthetized rats.
Kara AF; Demiryürek S; Celik A; Tarakçioğlu M; Demiryürek AT
Fundam Clin Pharmacol; 2006 Oct; 20(5):449-59. PubMed ID: 16968415
[TBL] [Abstract][Full Text] [Related]
32. The effectiveness of preoperative trimetazidine on myocardial preservation in coronary artery bypass graft patients: a systematic review and meta-analysis.
Zhang N; Lei J; Liu Q; Huang W; Xiao H; Lei H
Cardiology; 2015; 131(2):86-96. PubMed ID: 25871315
[TBL] [Abstract][Full Text] [Related]
33. Trimetazidine in cardiovascular medicine.
Marzilli M; Vinereanu D; Lopaschuk G; Chen Y; Dalal JJ; Danchin N; Etriby E; Ferrari R; Gowdak LH; Lopatin Y; Milicic D; Parkhomenko A; Pinto F; Ponikowski P; Seferovic P; Rosano GMC
Int J Cardiol; 2019 Oct; 293():39-44. PubMed ID: 31178223
[TBL] [Abstract][Full Text] [Related]
34. Role of trimetazidine in management of ischemic cardiomyopathy.
Bertomeu-Gonzalez V; Bouzas-Mosquera A; Kaski JC
Am J Cardiol; 2006 Sep; 98(5A):19J-24J. PubMed ID: 16931202
[TBL] [Abstract][Full Text] [Related]
35. Anti-Ischemic Activity of n-Tyrozol under Conditions of Repeated Transient Myocardial Ischemia in Rats.
Plotnikov MB; Chernysheva GA; Smol'yakova VI; Plotnikova TM; Sysolyatin SV; Kryukov YA
Bull Exp Biol Med; 2018 Sep; 165(5):625-628. PubMed ID: 30225710
[TBL] [Abstract][Full Text] [Related]
36. [The efficacy of complex therapy of ventricular arrhythmias with emoxipin and preductal in combination with antiarrhythmic agents].
Kotliarov AA; Mosina LM; Kairakina TN; Chibisov SM; Kulikov SI
Klin Med (Mosk); 2007; 85(12):22-6. PubMed ID: 18318161
[TBL] [Abstract][Full Text] [Related]
37. The protective effect of trimetazidine on myocardial ischemia/reperfusion injury through activating AMPK and ERK signaling pathway.
Liu Z; Chen JM; Huang H; Kuznicki M; Zheng S; Sun W; Quan N; Wang L; Yang H; Guo HM; Li J; Zhuang J; Zhu P
Metabolism; 2016 Mar; 65(3):122-30. PubMed ID: 26892523
[TBL] [Abstract][Full Text] [Related]
38. Pre-ischaemic mitochondrial substrate constraint by inhibition of malate-aspartate shuttle preserves mitochondrial function after ischaemia-reperfusion.
Jespersen NR; Yokota T; Støttrup NB; Bergdahl A; Paelestik KB; Povlsen JA; Dela F; Bøtker HE
J Physiol; 2017 Jun; 595(12):3765-3780. PubMed ID: 28093764
[TBL] [Abstract][Full Text] [Related]
39. [Assessment of Efficacy and Safety of Metabolic Therapy With Trimetazidine MB in Patients With Ischemic Heart Disease and Chronic Heart Failure].
Gorbunova ML; Vilkova AV
Kardiologiia; 2016 Mar; 56(3):67-72. PubMed ID: 28294892
[TBL] [Abstract][Full Text] [Related]
40. Effects of trimetazidine on myocardial perfusion and the contractile response of chronically dysfunctional myocardium in ischemic cardiomyopathy: a 24-month study.
El-Kady T; El-Sabban K; Gabaly M; Sabry A; Abdel-Hady S
Am J Cardiovasc Drugs; 2005; 5(4):271-8. PubMed ID: 15984909
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
